Atom | NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

Due Dates: May 28, 2025 | September 23, 2025 | January 24, 2026 | May 27, 2026 (Letter of Intent) | September 23, 2026

Funding Amounts: Up to $1,000,000 total costs per year; maximum $2,000,000 total costs for the entire project period (up to 3 years for Phase II/IIB).

Summary: Supports U.S. small businesses conducting early-stage, greater-than-minimal-risk clinical trials for interventions targeting vision disorders.

Key Information: Applicants must consult NEI program staff before submission; only Phase II/IIB or Direct-to-Phase II applications are allowed.

NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

Sign in to see full grant listing